( MENAFN - PR Newswire) The regulatory approval process with the U.S. Food and Drug Administration has commenced for Innocan's LPT-CBD release technology, marking a key step in the advancement of non-opioid pain management HERZLIYA, Israel and CALGARY, AB, May 21, 2024 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF ) ("Innocan" or the "Company"), is pleased to announce significant advancements in the regulatory process for its Liposome-Cannabidiol (LPT-CBD) technology, which provides an innovative solution in non-opioid pain management.
The U.S. Food and Drug Administration ("FDA") has granted Innocan an Investigational New Drug ("IND") number and approved an initial meeting with the Company to discuss the strategic path forward.
The meeting with the FDA has been set for July 31, 2024, where Innocan will present its preclinical results and proposed clinical development plan. This meeting is key to launching human clinical trials for the LPT-CBD injectable drug, developed to provide a novel treatment option for chronic pain. "We are very pleased with this crucial step towards launching our IND program for LPT-CBD in the United States," commented Iris Bincovich CEO of Innocan Pharma.
"This upcoming FDA consultation is pivotal, poised to set the stage for our clinical trials and drive forward our mission to revolutionize pain management. We look forward to the FDA reviewing our development program and providing us with guidance on our advancement.
